

# Hajimu Kurumatani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6921949/publications.pdf>

Version: 2024-02-01

13  
papers

186  
citations

1163117

8  
h-index

1125743

13  
g-index

14  
all docs

14  
docs citations

14  
times ranked

234  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Prostacyclin Analog Beraprost Sodium Ameliorates Characteristics of Metabolic Syndrome in Obese Zucker (Fatty) Rats. <i>Diabetes</i> , 2010, 59, 1092-1100.	0.6	50
2	Amelioration by beraprost sodium, a prostacyclin analogue, of established renal dysfunction in rat glomerulonephritis model. <i>European Journal of Pharmacology</i> , 2002, 449, 167-176.	3.5	27
3	Beraprost sodium improves survival rates in anti-glomerular basement membrane glomerulonephritis and 5/6 nephrectomized chronic kidney disease rats. <i>European Journal of Pharmacology</i> , 2013, 714, 325-331.	3.5	22
4	Orally active prostacyclin analogue beraprost sodium in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled, phase II dose finding trial. <i>BMC Nephrology</i> , 2015, 16, 165.	1.8	18
5	Effect of beraprost sodium (BPS) in a new rat partial unilateral ureteral obstruction model. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2009, 80, 263-267.	2.2	13
6	Comparative effects of beraprost, a stable analogue of prostacyclin, with PGE1, nitroglycerin and nifedipine on canine model of vasoconstrictive pulmonary hypertension. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2001, 64, 197-202.	2.2	11
7	A prostacyclin analog prevents the regression of renal microvascular network by inhibiting mitochondria-dependent apoptosis in the kidney of rat progressive glomerulonephritis. <i>Prostaglandins and Other Lipid Mediators</i> , 2014, 112, 16-26.	1.9	10
8	A Double-blind, Placebo-controlled, Multicenter, Prospective, Randomized Study of Beraprost Sodium Treatment for Cats with Chronic Kidney Disease. <i>Journal of Veterinary Internal Medicine</i> , 2018, 32, 236-248.	1.6	8
9	The Pharmacokinetics of Beraprost Sodium Following Single Oral Administration to Subjects With Impaired Kidney Function. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 524-535.	2.0	7
10	Effects of Sustained-release Beraprost in Patients With Primary Glomerular Disease or Nephrosclerosis: CASSIOPEIR Study Results. <i>Therapeutic Apheresis and Dialysis</i> , 2020, 24, 42-55.	0.9	7
11	A multinational phase IIb/III trial of beraprost sodium, an orally active prostacyclin analogue, in patients with primary glomerular disease or nephrosclerosis (CASSIOPEIR trial), rationale and study design. <i>BMC Nephrology</i> , 2014, 15, 153.	1.8	6
12	Prostacyclin analog beraprost sodium efficacy in primary glomerular disease or nephrosclerosis: Analysis of the Japanese subgroup in CASSIOPEIR study. <i>Therapeutic Apheresis and Dialysis</i> , 2021, 25, 551-564.	0.9	3
13	Comparison of Pharmacokinetic Profiles of Beraprost Sustained Release in Japanese, Chinese, and Korean Healthy Adult Males. <i>Clinical Drug Investigation</i> , 2021, 41, 549-555.	2.2	0